Citadel Advisors’s Gossamer Bio GOSS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.2K Sell
925
-1,215
-57% -$27.1K ﹤0.01% 13477
2026
Q1
$56.2K Sell
2,140
-1
-0% -$126 ﹤0.01% 12358
2025
Q4
$531K Buy
2,141
+1,027
+92% +$234K ﹤0.01% 8880
2025
Q3
$234K Buy
1,114
+396
+55% +$69.8K ﹤0.01% 10890
2025
Q2
$70.6K Sell
718
-5
-0.7% -$436 ﹤0.01% 11580
2025
Q1
$63.6K Sell
723
-291
-29% -$26.9K ﹤0.01% 12041
2024
Q4
$73.4K Buy
1,014
+360
+55% +$24.7K ﹤0.01% 11904
2024
Q3
$51.6K Sell
654
-74
-10% -$5.7K ﹤0.01% 11872
2024
Q2
$52.4K Buy
728
+630
+643% +$37.7K ﹤0.01% 11706
2024
Q1
$9.2K Buy
98
+29
+42% +$2.55K ﹤0.01% 13514
2023
Q4
$5.02K Sell
69
-9
-12% -$532 ﹤0.01% 13464
2023
Q3
$5.16K Sell
78
-47
-38% -$4.33K ﹤0.01% 13417
2023
Q2
$12K Sell
125
-391
-76% -$39K ﹤0.01% 13105
2023
Q1
$52K Sell
516
-789
-60% -$121K ﹤0.01% 12096
2022
Q4
$227K Buy
1,305
+981
+303% +$646K ﹤0.01% 9895
2022
Q3
$310K Buy
+324
New +$322K ﹤0.01% 9499
2022
Q2
– Sell
-453
Closed -$314K – 13320
2022
Q1
$314K Buy
453
+262
+137% +$202K ﹤0.01% 10492
2021
Q4
$173K Buy
+191
New +$181K ﹤0.01% 12068
2021
Q3
– Sell
-3,246
Closed -$2.11M – 14103
2021
Q2
$2.11M Sell
3,246
-5
-0.2% -$3.47K ﹤0.01% 6484
2021
Q1
$2.41M Buy
3,251
+2,778
+587% +$2.24M ﹤0.01% 5966
2020
Q4
$366K Buy
473
+90
+23% +$70.9K ﹤0.01% 8723
2020
Q3
$380K Buy
383
+224
+141% +$238K ﹤0.01% 7754
2020
Q2
$165K Buy
159
+11
+7% +$11.1K ﹤0.01% 8673
2020
Q1
$120K Sell
148
-615
-81% -$642K ﹤0.01% 8492
2019
Q4
$953K Sell
763
-2,647
-78% -$4.27M ﹤0.01% 5672
2019
Q3
$4.58M Buy
+3,410
New +$5.42M ﹤0.01% 3236

Other funds holding GOSS

Citadel Advisors's GOSS Position: Q1 2026 in Review

Citadel Advisors sold out of Gossamer Bio (GOSS) in Q1 2026, closing a stake of 8,810 shares — an estimated $1.11M sold.

Citadel Advisors first reported a position in GOSS in Q1 2019 and held it in 27 quarters. The position peaked at $21.2M in Q4 2021. 182 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

  • Citadel Advisors reported no remaining Gossamer Bio position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 8,810 Gossamer Bio shares in Q1 2026, an estimated $1.11M.
  • Citadel Advisors first reported a position in Gossamer Bio in Q1 2019 and held it in 27 quarters.
  • Citadel Advisors's Gossamer Bio position peaked at $21.2M in Q4 2021.
  • 182 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.